With Apogee Therapeutics currently bound by a definitive all-cash acquisition agreement with AbbVie at a fixed purchase price per share, the stock typically trades very close to the agreed buyout offer threshold. Purchasing shares at this stage generally offers limited upside restricted to deal-arbitrage margins, while carrying standard regulatory closure risks inherent in large pharmaceutical mergers.